Paradigm Therapeutics
Paradigm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies to address critical medical needs in the treatment of rare diseases. Their primary focus is the treatment of Epidermolysis Bullosa (EB). SD-101, Paradigm's leading therapy, is a topical cream for treating skin effects in EB patients, currently having completed Phase II and Phase III clinical trials.
Funding Round: Strategic Investment
Funding Amount: $12.6M
Date: 18-Jun-2025
Investors: Eshelman Ventures, LLC
Markets: Biotech, Pharmaceuticals, Dermatology
HQ: Mount Pleasant, South Carolina, United States
Founded:
Website: https://www.paradigmtherapeutics.com/
LinkedIn: https://www.linkedin.com/company/paradigm-therapeutics-inc
Leave a Comment
Comments
No comments yet.